Trillium Therapeutics’ TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 11/13/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical and clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented this weekend at the Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbor, Maryland USA.Poster Presentation P42: The checkpoint inhibitor TTI-621 (SIRPalphaFc) stimulates innate and adaptive immune responses in patien [...]


read full post from firmenpresse

(164893 Posts)

Leave a Reply